Clinical Trials

Clinical trial to determine whether antibiotics can boost immune response in treating liver cancer

A new clinical trial at the NCI’s Center for Cancer Research is set to explore if eliminating certain bacteria in the gut will boost the immune system response in patients who have hepatocellular carcinoma and liver metastases.

New clinical trial tests radiotracer for improved imaging of metastatic prostate cancer

Most forms of prostate cancer have receptors for prostate-specific membrane antigen (PSMA), a protein that helps fuel the development of prostate cancer cells. Investigators are studying if a radiotracer that binds to PSMA may improve imaging methods to find sites of metastatic prostate cancer.

Clinical trial tests a PARP inhibitor in urothelial cancer with DNA-repair defects

Urothelial carcinoma (UC), or bladder cancer, is the most common cancer of the urinary tract with limited treatment options. A new clinical trial aims to see how this type of cancer reacts to olaparib, a drug designed to target cancers that have defective DNA-repair mechanisms in their cells by inhibiting the action of PARP, an enzyme that can repair breaks in DNA.

New study delivers chemotherapy to the liver for metastatic colorectal cancer patients

In some patients, colorectal cancer spreads only to the liver. Patients with previously treated colorectal cancer that has spread only to the liver may be eligible to participate in a new clinical trial at the NIH Clinical Center.

New clinical trial will determine if gliomas respond to immunotherapy

Gliomas make up about 80 percent of all malignant brain tumors. A new clinical trial at the Center for Cancer Research is investigating if the immunotherapy drug nivolumab is beneficial to patients with gliomas.

Micrograph of a diffuse large B cell lymphoma

Trial results show that younger lymphoma patients respond well to ibrutinib

A recent clinical trial using the drug ibrutinib reveals that patients under age 60 with diffuse large B-cell lymphoma are much more likely to tolerate the drug – and respond to it – compared to those age 60 and older.

New clinical trial recruits the immune system to attack chronic lymphocytic leukemia

Chronic lymphocytic leukemia (CLL) is cancer that develops in blood-forming cells in the bone marrow. A new clinical trial is testing a way to boost the body’s natural immune cells and recruit them to attack and kill marked leukemia cells.

Clinical trial studies antitumor effect of sunitinib in central nervous system sarcomas

A new clinical trial is testing a cancer drug, sunitinib, on recurrent gliosarcoma and previously treated sarcomas of the central nervous system. This drug has been studied in several other types of cancer, where it was able to inhibit factors that help tumors grow and spread. Investigators want to see if sunitinib can have the same antitumor effect on sarcomas and gliosarcoma of the brain and spinal cord.

Clinical trial finds combination therapy effective for some biliary cancer patients

Completion of a phase I/II clinical trial found that two of 20 patients with biliary tract cancer disease experienced a partial response to treatment with the immune checkpoint inhibitor tremelimumab combined with microwave ablation therapy. Further studies are needed to understand why just a few patients responded well to this combination treatment.

New imaging technology to detect early-stage hereditary diffuse gastric cancer tested in clinical trial

Hereditary diffuse gastric cancer is a rare inherited condition caused by a mutation in the CDH1 gene. People who carry this genetic mutation are urged to have a screening endoscopy followed by surgery to remove the stomach. However, some patients elect to have regular endoscopic screenings to look for cancer. A new clinical trial is testing an imaging technology called confocal endoscopic microscopy (CEM) that may better detect cells in patients with the CDH1 mutation and potentially make a diagnosis during the endoscopy itself.

Breadcrumb